Navigation Links
Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target

any diabetes drug for an eight- week period. Patients were then randomized to receive one of four once-daily doses of liraglutide (0.1, 0.3, 0.6, and 0.9 mg) or placebo. Baseline A1c levels ranged between 8.1 to 8.5%. The randomized, 14-week study showed statistically significant dose-dependent reductions in A1c levels (ranging from 0.79 to 1.85 percentage points - placebo adjusted, p<0.0001) after once- daily dosing of liraglutide monotherapy in these patients. Further, A1c levels below 7 percent were achieved by 22, 43, 62 and 75 percent of patients receiving liraglutide 0.1, 0.3, 0.6 and 0.9 mg/day compared with 9 percent of those receiving placebo. Additionally, in these normal-weight subjects (average BMI 23.9) no relevant changes in body weight or major or minor hypoglycemic events occurred in any study group.(1)

The main gastrointestinal adverse events in the high dose group versus placebo were: constipation (7% versus 9%), diarrhea (9% versus 4%), gastritis (7% vs. 0%) and nausea (7% versus 2%). No subject had a treatment-related increase in liraglutide antibodies.

About liraglutide

Currently in phase 3 clinical trials, liraglutide is a human analog of the naturally occurring hormone, Glucagon-Like Peptide-1 (GLP-1), which is rapidly broken down in the body and thus not practical as a therapy for type 2 diabetes. GLP-1 is released from the gastrointestinal tract upon ingestion of food. When glucose levels become too high, GLP-1 triggers the release of insulin from the pancreas and decreases the secretion of glucagon, a hormone that promotes glucose synthesis in the liver. GLP-1 releases insulin in a glucose-dependent manner, meaning that it only triggers insulin secretion if blood glucose is too high. This characteristic is thought to result in a low risk of hypoglycemia, which has been confirmed in a number of studies in which GLP-1 was infused intravenously or subcutaneously.

Novo Nordisk is a healthcare company and a world lead
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... MELBOURNE, Australia, Oct. 24, 2011 Key Points ... 2 trial for wet Age-related Macular Degeneration (AMD) ... Mesoblast,s allogeneic ("off-the-shelf") cells with anti-VEGF agent Wet AMD, ... forms in Asia and North America/Europe Anti-VEGF agents are ...
... today announced that it has received the Stroke Care ... placing it among the top 5 percent of hospitals ... mortality rates for stroke treatment and pulmonary services. ... with HealthGrades, Five-Star Rating and ranked as the number ...
Cached Medicine Technology:Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases 2Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases 3Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases 4Evergreen Named One of America's 100 Best Hospitals for Stroke Care 2Evergreen Named One of America's 100 Best Hospitals for Stroke Care 3
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
(Date:4/17/2014)... therapy improves general blood flow and alleviates muscle ... researchers at the University of Illinois at Chicago. ... print in the Archives of Physical Medicine ... vascular function in people who had not exercised, ... of their level of physical activity. , Improved ...
(Date:4/17/2014)... of Canadians surveyed said they would participate in public ... of genetic conditions, only 80 per cent said they ... sequence their newborns, genomes.,Most newborns in North America have ... two of life in which a tiny amount of ... about five to 54 conditions, depending on the state ...
(Date:4/17/2014)... as the leading weapon against the deadly disease could ... research indicating it simply needs to be administered differently. ... cheap anti-malarial drug chloroquine in treating and preventing the ... half a million people each year around the world. ... to chloroquine, but research carried out at the Australian ...
(Date:4/16/2014)... Ariz. April 15, 2014 The Translational Genomics ... at their annual Founders Dinner for their support of ... event took place March 28 in Scottsdale. , Catherine ... Ivy Foundation, received TGen,s John S. McCain Leadership Award, ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... of interoperable Health Information Technology (HIT) will be ... the U.S. healthcare system," Yul D. Ejnes, MD, FACP, ... Health today. "Unfortunately, without adequate financial incentives, small ... technological curve." Dr. Ejnes, a member of the Board ...
... launches first of three-part series, MONTCLAIR, N.J., July ... the launch of an educational Webcast series on,chronic pain ... chronic pain sufferer, Nikki Stone. The first in the,three-part ... You Back" is available today at http://www.painawareness.org ., ...
... July 24 Colombia has appointed Dallas sports,chiropractor, Dr. ... medical team,during the upcoming Olympic Games in Beijing. Dr. ... worked with the Costa,Rican team for the 2007 Pan ... a privilege to bring the profession to an international ...
... BURLINGTON, Mass., July 24 Palomar Medical,Technologies, Inc. (Nasdaq: ... devices for hair removal and other cosmetic treatments, will,hold ... financial,results on Thursday, July 31, 2008 at 11:30AM Eastern ... 362-4831 at 11:20 AM Eastern Time on,that day. The ...
... The University of Queensland is helping to increase medical ... advanced clinical training facility. , UQ,s Rural Clinical ... and Learning Centre to its portfolio, with space to ... adjacent to the Toowoomba Base Hospital in West Street, ...
... new research facility is planned to enable unprecedented understanding ... shape human behaviour. The 28.5 million funding comes ... Universities and Skills (DIUS), and will be used for ... be a collaboration between the Economic and Social Research ...
Cached Medicine News:Health News:ACP says Medicare should increase payments for physicians that use HIT to improve quality 2Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 2Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 3Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 4Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 5Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 6Health News:Video: Olympic Games Gold Medalist Nikki Stone Joins Chronic Pain Experts in Educational Webcasts 7Health News:Colombia Appoints Dallas Chiropractor to Olympic Team 2Health News:Palomar Medical Technologies to Host Second Quarter 2008 Financial Results Conference Call and Webcast on July 31, 2008 2Health News:New $4.2m UQ medical center to boost rural doctor numbers 2Health News:£28.5M investment for groundbreaking new research facility 2
... Acid is a non-irritating rapid exfoliator. Lactic Acid ... to peel and exfoliating agents in skin care ... other exfoliators for a long period and want ... occurring human metabolite, and combined with the chemical ...
... is available in two innovative formulations: Level ... active). The Level I (40% active) formulation ... extract, which DCL scientists have identified and ... and calm the skin while the beneficial ...
... CosmoDerm and CosmoPlast are dermal fillers ... acne scars and other soft tissue contour ... of the lip border. The collagen in ... dermal tissue that is grown under controlled ...
... is a gel of ... species of bacteria, chemically ... suspended in phosphate,buffered saline ... and concentration of 20 ...
Medicine Products: